EP300 facilitates human trophoblast stem cell differentiation

• Published in: Proceedings of the National Academy of Sciences - PNAS 2023-07, Vol.120 (28), p.e2217405120-e2217405120
• Main Authors: van Voorden, A Jantine, Keijser, Remco, Veenboer, Geertruda J M, Lopes Cardozo, Solange A, Diek, Dina, Vlaardingerbroek, Jennifer A, van Dijk, Marie, Ris-Stalpers, Carrie, van Pelt, Ans M M, Afink, Gijs B
• Format: Article
• Language: English
• Subjects: Biological Sciences; Cell Differentiation; Cell proliferation; Complications; CREB-binding protein; CREB-Binding Protein - genetics; CRISPR; Cyclic AMP response element-binding protein; Developmental disabilities; Differentiation (biology); E1A-Associated p300 Protein - genetics; Epidermal growth factor receptors; ErbB Receptors; Female; Fetuses; Growth factors; Humans; Mutagenesis; Mutation; Organoids; Placenta; Pre-Eclampsia; Pregnancy; Pregnancy complications; Proteins; RNA-mediated interference; Rubinstein-Taybi Syndrome - genetics; Rubinstein-Taybi Syndrome - metabolism; Stem cells; Transcriptomes; Transforming Growth Factor alpha; Transforming growth factor-a; Trophoblasts - metabolism
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.2217405120

Early placenta development involves cytotrophoblast differentiation into extravillous trophoblast (EVT) and syncytiotrophoblast (STB). Defective trophoblast development and function may result in severe pregnancy complications, including fetal growth restriction and pre-eclampsia. The incidence of these complications is increased in pregnancies of fetuses affected by Rubinstein-Taybi syndrome, a developmental disorder predominantly caused by heterozygous mutations in CREB-binding protein ( ) or E1A-binding protein p300 ( ). Although the acetyltransferases CREBBP and EP300 are paralogs with many overlapping functions, the increased incidence of pregnancy complications is specific for mutations. We hypothesized that these complications have their origin in early placentation and that EP300 is involved in that process. Therefore, we investigated the role of EP300 and CREBBP in trophoblast differentiation, using human trophoblast stem cells (TSCs) and trophoblast organoids. We found that pharmacological CREBBP/EP300 inhibition blocks differentiation of TSCs into both EVT and STB lineages, and results in an expansion of TSC-like cells under differentiation-inducing conditions. Specific targeting by RNA interference or CRISPR/Cas9-mediated mutagenesis demonstrated that knockdown of but not inhibits trophoblast differentiation, consistent with the complications seen in Rubinstein-Taybi syndrome pregnancies. By transcriptome sequencing, we identified transforming growth factor alpha (TGFA, encoding TGF-α) as being strongly upregulated upon knockdown. Moreover, supplementing differentiation medium with TGF-α, which is a ligand for the epidermal growth factor receptor (EGFR), likewise affected trophoblast differentiation and resulted in increased TSC-like cell proliferation. These findings suggest that EP300 facilitates trophoblast differentiation by interfering with at least EGFR signaling, pointing towards a crucial role for EP300 in early human placentation.